title: Metabonomic evaluation of Schaedler altered microflora rats.
abstract: Previously, we identified two distinct metabonomic phenotypes in Sprague-Dawley rats sourced from two different rooms (colonies) in the Charles River, Raleigh facility [Robosky, L. C., Wells, D. F., Egnash, L. A., Manning, M. L., Reily, M. D., and Robertson, D. G. (2005) Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci. 87, 277-284]. On the basis of literature reports and cohabitation experiments, we concluded that the differing phenotypes were due to different gut flora populations. One hypothesis explaining this phenomenon was attributed to the practice of initiating new colonies with rats derived from foundation colonies that had limited gut floral populations, the Charles River altered Schaedler flora (CRASF) rats. We hypothesized that the lack of differentiation of CRASF rats to the full complement of microflora was responsible for the altered phenotype characterized by increased urinary chlorogenic acid metabolites and decreased hippurate (CA rats) as opposed to the prevalent phenotype characterized by the inverse ratio of these metabolites (HIP rats). Upon receipt, it was confirmed that the CRASF rats exhibited a metabonomic profile similar to CA rats that remained constant while animals were housed individually in a dedicated animal room. However, exposure of CRASF rats to HIP rats, or their bedding, led to a relatively rapid but variable rate of reversion to the historic HIP type metabolic profile. On the basis of the results, we conclude that CRASF rats have a unique metabolic profile due to their limited gut flora constitution. If rigorous isolation procedures are not employed, the CRASF phenotype will eventually differentiate into the more typical HIP phenotype with a time course that may be quite variable. Given the marked metabolic heterogeneity between the phenotypes, this work highlights the importance of monitoring rat metabolic profiles.
authors: Metabonomics Evaluation Group, Pfizer Global Research and Development, An Arbor, MI 48105, USA. rohdec@wyeth.com
authors: Cynthia M
authors: CM
authors: Rohde
authors: Dale F
authors: DF
authors: Wells
authors: Lora C
authors: LC
authors: Robosky
authors: Matthew L
authors: ML
authors: Manning
authors: Charles B
authors: CB
authors: Clifford
authors: Michael D
authors: MD
authors: Reily
authors: Donald G
authors: DG
authors: Robertson
mesh_terms: D000818:Animals; D001419:Bacteria / Q000254:growth & development / Q000378:metabolism*; D002726:Chlorogenic Acid / Q000652:urine; D005260:Female; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006626:Hippurates / Q000652:urine; D006798:Housing; D008297:Male; D008660:Metabolism; D010641:Phenotype; D051381:Rats; D017207:Rats, Sprague-Dawley / Q000378:metabolism* / Q000382:microbiology*
chemical_list: D006626:Hippurates; D002726:Chlorogenic Acid